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Whether use of various types of hormonal contraception (HC) affect risk of HIV acquisition is a critical question for women's health. For
this systematic review, we identified 22 studies published by January 15, 2014 which met inclusion criteria; we classified thirteen studies as
having severe methodological limitations, and nine studies as “informative but with important limitations”. Overall, data do not support an
association between use of oral contraceptives and increased risk of HIV acquisition. Uncertainty persists regarding whether an association
exists between depot-medroxyprogesterone acetate (DMPA) use and risk of HIV acquisition. Most studies suggested no significantly
increased HIV risk with norethisterone enanthate (NET-EN) use, but when assessed in the same study, point estimates for NET-EN tended to
be larger than for DMPA, though 95% confidence intervals overlapped substantially. No data have suggested significantly increased risk of
HIV acquisition with use of implants, though data were limited. No data are available on the relationship between use of contraceptive
patches, rings, or hormonal intrauterine devices and risk of HIV acquisition. Women choosing progestin-only injectable contraceptives such
as DMPA or NET-EN should be informed of the current uncertainty regarding whether use of these methods increases risk of HIV
acquisition, and like all women at risk of HIV, should be empowered to access and use condoms and other HIV preventative measures.
Programs, practitioners, and women urgently need guidance on how to maximize health with respect to avoiding both unintended pregnancy
and HIV given inconclusive or limited data for certain HC methods.
Published by Elsevier Inc.Keywords: Hormonal contraception; DMPA; Injectable contraception; Oral contraception; HIV acquisition; Systematic review1. Introduction
Whether various types of hormonal contraception (HC)
affect the risk of HIV acquisition remains a critical question
for women's health, particularly in populations where HIV is☆ Disclaimer: The findings and conclusions in this report are those of
the authors and do not necessarily represent the official position of the
United States Agency for International Development, the Centers for
Disease Control and Prevention, or the World Health Organization.
⁎ Corresponding author. 1201 Pennsylvania Ave NW, Suite 315,
Washington, DC, 20004. Tel.: +1 202 808 3800.
E-mail address: cpolis@usaid.gov (C.B. Polis).
http://dx.doi.org/10.1016/j.contraception.2014.07.009
0010-7824/Published by Elsevier Inc.common. In 2012, the World Health Organization (WHO)
convened a group of 75 experts to review epidemiological,
biological, and other data on this issue, and concluded by
consensus that WHO should recommend no restriction on
use of any method of HC for women at high risk of HIV.
However, the group added a clarification that, because of
the inconclusive nature of the evidence relating to
progestin-only injectables, women at high risk for HIV
who choose progestin-only injectables should be strongly
advised to always use male or female condoms and to take
other HIV preventive measures (see technical statement [1]
for full clarification).
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and HIV acquisition conducted for the 2012 WHO meeting
included all relevant studies published (or in press) byDecember
15, 2011 [2]. Separate systematic reviews examined the
epidemiological evidence on two related issues: whether various
methods of HC affect HIV disease progression in women living
with HIV [3] or female-to-male HIV transmission [4].
Following the 2012 WHO consultation, the global health
community responded with new modeling analyses [5–8],
anatomical, microbiological, and immunological data [9–24],
supplementary epidemiological analyses [25,26], commentar-
ies [27–29], overviews and guideline updates based on the
systematic reviews [30–33], technical briefings [34], and
analytical recommendations for future observational analyses
ofHC andHIV acquisition [35]. Conversations continue about
the feasibility and scientific benefit of a randomized trial of
various HC methods and HIV risk [28,36,37].
This issue is of substantial public health importance: for
example, one impact simulation model estimated that if
injectable contraception increases HIV risk by 20%, this
would contribute to 27,000 additional infections per year,
and that a doubling of HIV risk due to injectables would lead
to an additional 130,000 HIV infections per year — the vast
majority of which would occur in southern and Eastern
Africa [5]. On the other hand, the same model estimated that
if there is no causal effect of injectable contraception on HIV
acquisition, but injectable use decreases due to fears of this
possibility (and is not replaced by more effective contracep-
tive alternatives), we could expect a large increase in
unintended pregnancies, unsafe abortions, unintended births,
and at least 16,000 more maternal deaths per year worldwide,
largely in southern and eastern Africa and southern Asia.
Therefore, it is imperative that new data on this issue is
continually assessed and incorporated into our overall
understanding of this complex body of literature, to ensure
that contraceptive users, health care providers, and policy
makers have the maximum amount of information available
when making decisions. This paper updates the previous
systematic review on HC and HIV acquisition in women by
incorporating new epidemiological evidence published be-
tweenDecember 15, 2011, and January 15, 2014. Our goalwas
addressing the question of whether specific methods of HC
influence a woman's risk of HIV acquisition. Data included in
this systematic review were presented at a WHO meeting in
March 2014. Official WHO guidance on hormonal contracep-
tion and HIV stemming from that meeting is expected to be
disseminated in mid-2014. This systematic review was
conducted independently of the WHO guidance development
process, and served as an input in those deliberations.2. Methods
We conducted this systematic review according to
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) guidelines [38].2.1. Inclusion criteria
We included published primary research reports on
women who were HIV-negative at baseline in longitudinal
studies (observational studies or randomized trials) which
measured incident, laboratory-confirmed HIV infection
among women who used a specific method of HC
[injectables, oral contraceptives (OCs), implants, patches,
rings, or levonorgestrel intrauterine devices (IUDs)]
compared with incident HIV infection in women who
used either a non-hormonal contraceptive method (e.g.,
condoms, sterilization, withdrawal, etc.) or did not use a
contraceptive method.
We determined a priori that any study comparing incident
HIV infections among HIV-negative women using one
specific method of HC against HIV-negative women using
another method of HC (i.e., in a head-to-head comparison),
would provide indirect evidence of risk, and would thus be
discussed separately. We excluded cross-sectional studies
and studies that assessed only emergency contraception
(which is not typically used on a continual basis). We did not
include conference abstracts or other reports not published in
the peer-reviewed literature.2.2. Search strategy and data extraction
We relied upon our earlier systematic review to identify
articles published prior to December 15, 2011, and searched
PubMed and Embase for relevant articles published in any
language between December 15, 2011 and January 15, 2014.
We also hand-searched reference lists of related studies.
Appendix A details the complete search strategy. CBP
conducted the literature search and identified potentially
relevant articles; CBP and SJP read full text articles to
determine eligibility for inclusion. We used standardized
abstraction forms developed and used in a previous review to
extract relevant data [2]. When we needed to clarify details
of a particular analysis, we attempted to contact the study
authors directly.
2.3. Quality assessment
For comprehensiveness, we reviewed all studies that met
our inclusion criteria. However, many studies had severe
methodological flaws, and were considered unlikely to
contribute meaningfully to the evidence base. Therefore, our
main analysis focused on the studies we considered most
methodologically robust, using the study quality assessment
framework defined below. However, we note that all studies
had important limitations and should be considered in that
context. All authors participated in updating the study
quality assessment framework and in classifying each study
as either “informative but with important limitations” or
“unlikely to inform the primary question.”
Studies were considered “unlikely to inform the primary
question” if they had one or more of the following flaws:
Table A1
Description of studies, ordered by publication year
First author, publication
year, location
Design, purpose,
period of data
collection
Number enrolled,
description of
population
Results (point estimate
and 95% confidence
intervals)
Multivariate analysis
included condom use?
Met criteria for being
considered “Informative
but with important
limitations”?⁎
Plummer 1991 [43]
Nairobi, Kenya
Cohort; to determine
incidence and risk
factors for HIV
acquisition
1985–1987
196 sex workers Crude OR OCs: 3.1
(1.1–8.6)
adjOR OCs: 4.5
(1.4–13.8)
Stratified (no condom
use) crude OR OCs:
3.7 (1.1–11.4)
Crude HR OCs: not
reported, but log rank
pb.05.
Yes No. Unclear measurement
of exposure (no time-
varying HC exposure in
main analysis, referent
group included other
hormonal method users).
Additional limitations:
large loss to follow-up
(37% at 12 months).
Association between HC
and HIV was not primary
objective of either data
collection or data analysis.
Saracco 1993 [44]
Italy
Cohort; to determine
incidence and risk
factors for male-to-
female sexual
HIV transmission
in serodiscordant
couples
1987–1991
368 women in stable,
monogamous serodiscordant
relationships
None of the 22 OC
users became infected
vs. 19/283 non-users
No multivariate analysis No. Unclear measurement
of exposure (no time-
varying HC exposure,
referent group unclear).
Additional limitations:
association between HC
and HIV was not primary
objective of either data
collection or data analysis;
strong likelihood of
confounding, inability to
perform multivariate
analysis due to small
numbers of OC users.
Loss to follow-up unclear (7%
at 6 months, but median
follow-up time was 24 months).
Laga 1993 [45]
Kinshasa, Zaire
Nested case-control; to
determine if treatable
ulcerative and non-
ulcerative STD were
risk factors for HIV
1988
431 female sex workers Crude OR ever OC
use: 0.6 (0.2–2.4);
Crude OR OC use
during study: 0.7
(0.1–3.4);
Crude OR OC use
during exposure
interval: 0.9 (0–13.5)
No multivariate analysis No. No adjustment for condom
use and unclear measurement of
exposure (no time-varying HC exposure).
Additional limitations:
association between HC
and HIV was not primary
objective of either data
collection or data analysis.
Few OC users and minimal
OC use during exposure interval.
Information on total loss to follow-up
not provided (mean
monthly follow-up 76%).
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Bulterys 1994 [46]
Southern Rwanda
Cohort; to determine
incidence of HIV in
young, sexually active
women in Rwanda
1989–1993
1524 sexually active
women b30 years
old in mixed rural
and urban population
who were pregnant or
attending a prenatal
clinic
Crude OR ever HC
use: 3.2 (1.6–6.5)
Age-adjOR ever HC
uses: 2.9 (1.4–6.2)
adjOR ever HC use:
1.9 (0.8–4.6)
Results not provided
separately for OCs
and DMPA, but
“incidence of HIV
infection did not differ
by the type of HC
method used
(data not shown)”
Multivariate analysis
did not inclu
condom use
condom use rare
No, unclear measurement of
exposure (did not distinguish
between HC methods leading
to lack of clarity on utility of
estimates, HC use not
collected prospectively;
asked about use in past 24
months).
Additional limitations:
association between HC and
HIV was not primary objective
of either data collection or data
analysis.
Sinei 1996 [47]
Nairobi, Kenya
Nested case-control; pilot
study to demonstrate
feasibility of larger study.
1990–1992
1537 women in a
family planning clinic
Crude OR for OC
use in last 6 months:
3.5 (0.8–21.5)
Attempted to adjust for
multiple confounders
including condom use,
but association persisted
No, and esti from
multivariate sis not
provided
No, unclear measurement of
exposure (no time-varying HC
exposure), and condom use not
addressed.
Additional limitations: high
loss to follow-up (71% at 12
months).
Ungchusak 1996 [48]
Khon Kaen, Thailand
Cohort; to investigate risk
factors of HIV
1990–1991
365 sex workers in 24
illegal brothels in
Thailand
Crude IRR OCs: 0.17
(p=.11, 95% CI not
provided)
adjIRR OCs: 0.22
(0.03–1.87)
Crude IRR inj: 2.90
(p=.06, 95% CI not
provided)
adjIRR inj: 3.91
(1.29–11.82)
(based on comment
published after original
publication) [83]
Multivariate ysis
did not inclu ondom
use
No, unclear measurement of
exposure (no time-varying HC
exposure), and condom use not
addressed.
Additional limitations:
association between HC and
HIV was not primary objective
of either data collection or data
analysis. High loss to
follow-up; 34% at 3 months.
Kilmarx 1998 [49]
Chiang Rai, Thailand
Cohort; to examine
demographic, behavioral,
and other STIs associated
with HIV infection in
FSWs
1991–1994
340 sex workers in
STD clinic, medical
clinic, or workplace
Crude RR OCs: 2.5
(1.1–5.3)
adjRR OCs: 1.8
(0.8–4.0)
Crude RR DMPA:
1.5 (0.6–4.0)
adjRR DMPA: N/A
Multivariate ysis
did not inclu ondom
use
No, unclear measurement of
exposure (referent group
contains women using other
forms of HC), and
multivariate analysis does
not include condom use.
Additional limitations:
association between HC and
HIV was not primary objective
of either data collection or data
analysis. High loss to
follow-up (29% at 12 months,
46% at 24 months), and
differential loss to follow-up.
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Table A1 (continued)
First author, publication
year, location
Design, purpose,
period of data
collection
Number enrolled,
description of
population
Results (point estimate
and 95% confidence
intervals)
Multivariate analysis
included condom use?
Met criteria for being
considered “Informative
but with important
limitations”?⁎
Kapiga 1998 [50]
Dar Es Salaam,
Tanzania
Cohort; to study HIV
incidence in low-risk
women and examine
associations with
contraceptive methods
1991–1995
2471 women in three
family planning clinics
in Dar es Salaam
Age-adjusted HR
OCs: 1.28 (0.58–2.81)
adjHR OCs: 1.01
(0.45–2.28)
Age-adjusted HR
injectables: 0.27 (0.06–1.12)
adjHR injectables:
0.30 (0.07–1.26)
Analyses on duration of
HC use were not
statistically significant
for any method.
Stratified on condom
use: “adjusted results
not altered”
Considered controlling
for condom use in
multivariate analysis
No, unclear measurement
of exposure (no time-
varying HC exposure
(ever/never during follow up).
Additional limitations:
high loss to follow-up
(44.5%, unclear at what
time point), and differential
loss to follow-up. Frequency
of follow-up visits unclear
and may have varied by participant.
Kiddugavu 2003 [51]
Southwestern Uganda
Cohort; ongoing
population-based
cohort established as
part of a community
randomized trial
1994–1999
5117 sexually active
women aged 15–49
years
adjIRR any HC: 0.94
(0.53–1.64)
Crude IRR OCs: 1.70
(0.85–3.04)
adjIRR OCs: 1.12
(0.48–2.56)
Crude IRR injectable:
1.47 (0.82–2.45)
adjIRR injectable:
0.84 (0.41–1.72)
Stratified by no condom use:
Crude IRR any HC:
1.59 (0.90–2.66)
Yes No. The intersurvey interval was
10 months, with contraceptive use
collected only at each interval
endpoint.
Note, this study was considered
to meet minimum quality criteria
in our previous review.
Baeten 2007 [52]
(update of Martin
1998 [84]and Lavreys
2004 [66])
Mombasa, Kenya
Cohort; to define
HIV seroincidence in
female CSWs and
examine relationship
between HC, STDs,
and HIV incidence
1993–2003
1498 female sex
workers attending
clinic for STD
Crude HR OCs: 1.58
(1.12–2.24)
adjHR OCs: 1.46
(1.00–2.13)
Crude HR DMPA:
2.05 (1.56–2.70)
adjHR DMPA: 1.73
(1.28–2.34)
Yes Yes
Myer 2007 [53]
Cape Town, South
Africa
Cohort; RCT to
evaluate cervical
cancer screening
approaches
2000–2004
4555 women aged
35–65 enrolled in
a cervical cancer trial
All estimates based
on subset of participants
followed through 6 months
adjIRR OCs: 0.66 (0.09–4.78)
adjIRR NET-EN: 1.60
(0.63–4.09)
adjIRR DMPA: 0.75
(0.33–1.68)
Yes Yes; but only for estimates
based on participants followed
through 6 months; subsequent
visits had an intersurvey intervals
of greater than 6 months.
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Kleinschmidt 2007 [54]
Orange Farm, South
Africa
Cohort; to investigate
prospectively if HIV
incidence is higher
among sexually active
women using progestin
1999–2002
634 sexually active
women aged 18–40
Crude IRR injectables:
1.12 (0.45–2.78)
Crude IRR NET-EN:
1.77 (0.77–4.11)
adjIRR NET-EN:
1.76 (0.64–4.84)
Crude IRR DMPA:
0.26 (0.03–1.97)
adjIRR DMPA: 0.46
(0.06–3.79)
Stratified analysis
among “never”
condom users:
Crude IRR injectables:
0.8 (0.1–4.7)
Yes Yes
Kumwenda N 2008 [55]
Blantyre, Malawi
Cohort; RCT to assess
effect of intravaginal
antibiotic on genital
tract infections
2003–2005
842 non-pregnant
women of childbearing
age attending general
reproductive health
services, enrolled at a
central hospital or
one of two health
centers
Crude OR DMPA: 3.57
(1.37–9.31)
adjOR DMPA: 2.84
(1.07–7.55)
Multivariate analysis
did not include
condom use
No, no assessment of condom
use, and unclear measurement
of exposure (no use of
time-varying HC, and referent
group unclear, appears to
include women using other
methods of HC)
Additional limitations:
association between HC and
HIV was not primary objective
of either data collection or data
analysis; strong likelihood of
confounding.
Watson-Jones 2009 [56]
Northwestern Tanzania
Cohort; RCT assessing
effect of acyclovir on
HIV incidence
2004-end date unclear
821 HSV2+ women
aged 16–35 years
working in bars,
guesthouses, or
other food and
recreational facilities
Age-adjusted HR HC
at baseline: 1.17
(0.71–1.93)
Age-adjusted HR
current HC: 1.63
(0.95–2.80)
adjHR HC: 1.60
(0.93–2.76)
Multivariate analysis
did not include
condom use
No, unclear measurement of
exposure (did not distinguish
between HC methods), and
condom use not addressed.
Additional limitations:
association between HC and
HIV was not primary objective
of either data collection or
data analysis; strong likelihood
of confounding. Potentially
high loss to follow-up, unclear
(20% did not complete
follow-up defined as attending
until seroconversion or end of study).
Morrison 2010 [57]
(reanalysis of
Morrison 2007) [64]
Uganda, Zimbabwe
Cohort; to examine
association between
OC and DMPA use
and HIV
1999–2004
6,109 sexually-active,
non-pregnant women
in family planning
clinics, plus some
high-risk referral
women from STI or
primary healthcare
2010 MSM reanalysis:
Crude HR DMPA: n/a
adjHR DMPA: 1.48
(1.02–2.15)
Crude HR OCs: n/a
adjHR OCs: 1.19
(0.80–1.76)
Yes Yes
(continued on next page)
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Table A1 (continued)
First author, publication
year, location
Design, purpose,
period of data
collection
Number enrolled,
description of
population
Results (point estimate
and 95% confidence
intervals)
Multivariat lysis
included co use?
Met criteria for being
considered “Informative
but with important
limitations”?⁎
clinics, sex worker
networks, or military
bases.
2007 Cox PH analysis
Crude HR DMPA: 1.24
(0.90–1.71)
adjHR DMPA: 1.25
(0.89–1.78)
Crude HR OCs: 1.02
(0.72–1.43)
adjHR OCs: 0.99
(0.69–1.42)
2007 stratified analysis
restricted to no condom
use:
adjHR OCs: 1.47
(0.78–2.80)
adjHR DMPA: 1.61
(0.85–3.06)
Sensitivity analyses did
not change results.
Feldblum 2010 [58]
Nigeria, Ghana,
Benin, Uganda,
India, South Africa
Cohort; data from
four Phase III
RCTs on microbicides
2004–2007
7364 women at “higher
than average risk of
HIV” (variably defined
between studies)
Crude HR OCs: 1.84
(0.83–4.05)
Crude HR injectables:
2.51 (1.12–5.60)
“Use of injectable
contraception and
condom use were
significantly
associated
with incident HIV
initial models, but
dropped from the
final model; only age
and education were
significantly associated
with incident HIV in
the final model.”
Considered rolling
for condom in
multivariat lysis
No, unclear measurement of
exposure (no use of
time-varying information, all
covariates assessed at
baseline).
Additional limitations:
association between HC and
HIV was not primary objective
of either data collection or data
analysis. High loss to
follow-up in some but not all
sites (up to 30% in Nigeria
site).
Reid 2010 [41]
South Africa,
Zambia, Zimbabwe
Cohort; HPTN 039
study, RCT to assess
effect of acyclovir
on HIV incidence
2003–2007
1358 (analyzed, n
enrolled unclear) HSV2-
positive women recruited
from family planning,
well-baby, and VCT
clinics, and community
venues.
Crude HR OCs: 0.93
(0.48–1.82)
adjHR OCs: 0.91
(0.45–1.83)
Crude HR
injectables:
1.01 (0.51–1.98)
adjHR injectables:
0.94 (0.46–1.92)
Yes Yes
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Heffron 2012 [59]
Seven countries in
East and Southern
Africa
Cohort; RCT assessing
effect of acyclovir
on HIV incidence
2004–2010
1314 (analyzed, n
enrolled unclear)
M+F-serodiscordant
couples (83% of
observations from an
acyclovir RCT,
17% of observations
from cohort study
of immune correlates
of HIV protection)
HC
Crude HR (Cox):
1.73 (0.95–3.15)
adjHR (Cox): 1.98
(1.06–3.68)
adjOR (MSM): 1.84
(0.98–3.47)
OCs
Crude HR (Cox):
1.53 (0.48–4.90)
adjHR (Cox): 1.80
(0.55–5.82)
adjOR (MSM): 1.63
(0.47–5.66)
Injectables
Crude HR (Cox):1.80
(0.92–3.52)
adjHR (Cox): 2.05
(1.04–4.04)
adjOR (MSM): 2.19
(1.01–4.74)
Censoring at pregnancy
adjHR HC: 1.84
(0.97–3.49)
Yes Yes
Heffron 2012 [Authors' reply]
(Subanalysis of study
shown above)
[61]
Seven countries in
East and Southern Africa
New since last systematic
review
Same as above Same as above (n=1314),
except for certain sub-
analyses
Injectables; analysis
adding total number
of unprotected sex to
statistical model:
adjHR (Cox): 2.04
(1.03–4.04)
Injectables; analysis
replacing woman's
report of unprotected
sex with male partner's
report:
adjHR (Cox): 2.03
(0.95–4.32)
DMPA; analysis
excluding women
from South Africa
(who may use NET-EN)
(unpublished estimate) [65]:
adjHR (Cox): 2.04
(0.81–5.15)
DMPA; analysis
excluding women
from South Africa
and also excluding
women who switched
Yes Yes
(continued on next page)
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Table A1 (continued)
First author, publication
year, location
Design, purpose,
period of data
collection
Number enrolled,
description of
population
Results (point estimate
and 95% confidence
intervals)
Multivariat lysis
included co use?
Met criteria for being
considered “Informative
but with important
limitations”?⁎
contraceptive status at
any time in the study:
adjHR (Cox): 3.93
(1.38–11.22)
Morrison 2012 [60]
South Africa
Cohort; RCT assessing
the effectiveness of the
microbicide Carraguard,
2004–2007
5567 (analyzed, n
enrolled
unclear), recruited
from community
venues
OCs
adjHR (Cox): 0.88
(0.49–1.30)
adjHR (MSM): 0.84
(0.51–1.39)
DMPA
adjHR (Cox): 1.27
(0.93–1.73)
adjHR (MSM): 1.28
(0.92–1.78)
NET-EN
adjHR (Cox): 0.87
(0.60–1.25)
adjHR (MSM): 0.92
(0.64–1.32)
Yes Yes
Wand 2012 [42]
South Africa
Cohort; RCT assessing
the effectiveness of
vaginal microbicide,
dates of data collection
not provided
2236, recruited from
community venues
OCs
adjHR: 0.95 (0.62–1.46)
Injectables
adjHR: 2.02 (1.37–3.00)
DMPA adjHR: 1.61
(1.10–2.37) [85]
NET-EN adjHR: 2.54
(1.61–3.97) [85]
Yes Yes
Note: this study was
considered not to meet
minimum quality criteria in
our previous review given
concerns about the adequacy
of control for condom use.
McCoy 2013 [62]
South Africa and
Zimbabwe
New since last
systematic review
Cohort; RCT assessing
effectiveness of diaphragm
and lubricant gel for HIV
prevention, 2003–2006
4948 in HIV-endpoint
analytical dataset
(5048 enrolled).
Women reporting at
least 4 sex acts per
month recruited from
FP, well-baby, general
health clinics, community
based organizations, and
printed media and
radio
adjHR Cox, site-adjusted
only
OC overall: 0.82
(0.58–1.15)
COC: 0.78 (0.53–1.12)
POP: 0.91 (0.49–1.50)
Injectables overall: 1.32
(1.00–1.74)
DMPA: 1.18 (0.84–1.62)
NET-EN: 1.40
(0.72–2.35)
adjHR Cox, model
adjusted for baseline
covariates
OC overall: 0.84
(0.57–1.22)
Yes Yes
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COC: 0.80 (0.53–1.19)
POP: 0.94 (0.50–1.59)
Injectables overall:
1.27 (0.94–1.72)
DMPA: 1.22
(0.84–1.74)
NET-EN: 1.15
(0.58–1.95)
adjHR Cox, model
with robust standard
errors to account for
within-subject correlation
and separate baseline
hazards for each of the
three study sites,
adjusted for baseline and
time-varying covariates
COC: 0.86 (0.58–1.28)
POP: 0.98 (0.56–1.73)
Injectables overall: 1.37
(1.01–1.85)
DMPA: 1.28 (0.90–1.82)
[82]
NET-EN: 1.33 (0.76–2.33) [82]
adjHR IPTW MSM
Injectables overall: 1.34
(0.75–2.37)
OC overall: 0.86
(0.32–1.78)
Note: disaggregated
injectable Cox
estimates provided in
personal communication;
disaggregated
MSM injectable estimates
not possible due
to violation of the
positivity assumption.
Lutalo 2013 [63]
Rakai, Uganda
New since last
systematic review
Cohort; ongoing
population-based
cohort established
as part of a community
randomized trial
1999–2009
190 M+F-serodiscordant
couples retrospectively
identified from a cohort;
none using antiretroviral
therapy or condoms
adjIRR
OCs: 2.65 (0.82–8.60)
Implant: 0.89 (0.11–7.10)
DMPA: 1.42
(0.60–3.36)
adjIRR with consistent
use
OCs: 4.51 (0.74–27.45)
Implant: 1.47 (0.17–
12.67)
If condom u as
reported in a tudy
interval by a
participant, t
observation
excluded fro alysis.
Thus, condo se
was controll ia study
design, rathe n via
statistical co .
No. The intersurvey interval
ranged from between 12–16
months, with contraceptive
use collected only at each
interval endpoint.
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• Unclear measurement of exposure to HC, including
one or more of the following:
o Failure to include time-varying analysis of HC
exposure, if appropriate.
o Failure to provide separate estimates for different
types of HC methods (e.g., OCs or injectables or
implants). We did not exclude studies that grouped
together different formulations of a particular
method (e.g., combined depot-medroxyprogesterone
acetate (DMPA) and norethisterone enanthate (NET-
EN) into a single exposure category).
o Comparison group included a substantial or unclear
number of users of another HC method (except in an
intentional head-to-head comparison of a specific
HC method versus another specific HC method).
o The interval of time between study visits (“inter-
survey interval”) was longer than 6 months, with
contraceptive use measured only at each interval
endpoint (and thus providing only limited informa-
tion about possible contraceptive switching during
the intersurvey interval). (Note: if variation in length
of intersurvey interval occurred within an individual
study, such that some intervals were 6 months or less
and other intervals were longer than 6 months, we
included only data from intervals that were 6 months
or less).
Studies considered “informative but with important
limitations” had none of the flaws described above.
2.4. Graphical summaries
We created forest plots using Microsoft Excel 2007
(Microsoft, Redmond, WA, USA) to display the estimates
from each study of the association between various HC
methods and HIV risk, and generated funnel plots using
Review Manager 5 [39]. We created graphics to display all
available studies of a given method (i.e., OCs, injectables, or
implants), as well as separate graphics to display only studies
considered “Informative but with important limitations”. We
declined to include a statistical meta-analysis of these
observational data for methodological reasons. For example,
experts note that in observational data “potential biases in the
original studies, relative to biases in randomized controlled
trials, make the calculation of a single summary estimate of
effect of exposure potentiallymisleading.” [40]However, such
efforts are the focus of ongoing work by other groups [28].
Where possible, we have presented estimates for disaggre-
gated HC methods, and included both Cox and marginal
structural model (MSM) estimates when both were provided.
We emailed authors of “informative but with important
limitations” studies which included women from South Africa
(where use of both types of injectable, DMPA and NET-EN, is
common) but which did not report separate estimates for each,
and requested disaggregated estimates where possible. Disag-
gregated estimates of effect have reduced statistical power but
371C.B. Polis et al. / Contraception 90 (2014) 360–390are of more clinical importance, an important consideration
given the potential for different biological effects by contra-
ceptive type or formulation. All estimates from each study are
reported in Tables A1 and A2.3. Results
3.1. All included studies
Twenty eligible reports were included in the previous
review [41–60], and out of 400 references retrieved in our
updated search (Fig. 1), we identified one new eligible sub-
analysis of a previously included study [61] and two new
eligible studies [62,63]. None of these three new analyseswere
derived from studies designed specifically to assess the
relationship between HC and HIV acquisition; all were
secondary data analyses, and each included data from African
women. None of the studies included head-to-head compar-
isons of different HC methods.
Among 22 included studies (represented by 23
reports), 18 included estimates specific to OCs
[41–,47–53,57–60,62,63], 16 included estimates specific to
injectable contraception [41,42,48–55,57–60,62,63], and two
did not distinguish between methods of HC although the
investigators noted that most of the HC users used injectables
[46,56]. No eligible studies assessed the contraceptive patch,
ring, combined injectable, or levonorgestrel IUD.
Table A1 briefly describes all 23 reports (of 22 eligible
studies) and notes whether they met criteria for being
“informative but with important limitations”. Fig. 2 displays
the estimates from eighteen studies for OCs and Fig. 3 shows
the estimates for injectables (two studies with non-specified
methods of HC are included with the sixteen that reported
estimates specific to injectables). In Figs. 2 and 3 all studies
are displayed, regardless of methodological quality, and are
shown in decreasing order of effect size.
3.2. Studies considered “informative but with important
limitations”
Of 22 included studies, we considered thirteen “unlikely
to inform the primary question” [43–51,55,56,58,63], and
nine “informative but with important limitations” (Table A2)
[41,42,52–54,57,59–62,64]. Each of the “informative but
with important limitations” studies included or assessed the
need for statistical control for some measure of condom use,
age, number of sexual partners, and genital symptoms or genital
infection. Other factors, such as marital status, frequency of
sexual encounters, or partner risk, were accounted for only in
some of the studies (Table A3).
3.2.1. Oral contraceptives
Of the eight “informative but with important limitations”
studies that assessed OCs (Fig. 4), one reported a significant
increase in risk [p=.05; adjusted hazard ratio (adjHR) 1.5,
95% CI 1.0–2.1] [52]. The other studies reported non-
significant estimates [ranging from adjusted incidence rateratio (adjIRR) 0.66, 95% CI 0.09–4.78 to adjHR 1.80, 95%
CI 0.47–5.66] [41,42,53,57,59,60,62,64]. No substantial
differences were observed between combined oral contra-
ceptives (COCs) and progestin-only pills (POPs) in the one
study that disaggregated these methods [62].
3.2.2. Injectables
Of the nine “informative but with important limitations”
studies for injectables, four reported a significant increase in
risk with injectables [42,52,57,59], though the statistical
significance of one of these studies depended upon the
statistical method used. In that study, the association was
significant when MSM was used [57], but non-significant
when a Cox proportional hazards model was used [64]. The
confounders adjusted for in each of these two statistical
models differed slightly (Fig. 5) [57,64]. Estimates from
studies considered informative but with important limitations
that reported significant findings for injectables ranged from
adjHR 1.48, 95% CI 1.02–2.15 (specific to DMPA) [57] to
adjHR 2.54, 95% CI 1.61–3.97 (specific to NET-EN) [42].
Five studies reported non-statistically significant estimates
of effect in their primary analyses [41,53,54,60,62] (although
one had a significant result in an analysis combining NET-
EN and DMPA using a Cox proportional hazards model
[adjHR: 1.37, 95% CI 1.01–1.85] [62]); non-significant
estimates ranged from adjIRR 0.46, 95% CI 0.06–3.79 [54]
to adjIRR 1.76, 95% CI 0.64–4.84 [54]. No study found a
significantly decreased risk estimate.
Two studies reported estimates for DMPA and NET-EN
combined. Heffron et al. reported increased HIV risk
(ranging between adjHR 2.04, 95% CI 1.03–4.04 [Cox
estimate] and adjHR 2.19, 95% CI 1.01–4.74 [MSM
estimate], depending on the statistical method used) [59],
and Reid et al. reported an estimate of adjHR 0.94, 95% CI
0.46–1.92 [41]. Heffron et al. performed a new sub-analysis
excluding women from South Africa (who may have used
either NET-EN or DMPA), to attempt to isolate the effect of
DMPA. They reported a point estimate (adjHR 2.04, 95% CI
0.81–5.15) [65] similar to the primary findings but with
wider confidence intervals; this sub-analysis was based on
four seroconverters assumed to be using DMPA (estimate from
this restricted sub-analysis not shown in figures to avoid loss of
data due to fewer endpoints; complete disaggregation into
DMPA and NET-EN users was not possible in this analysis).
Of seven studies reporting DMPA-specific estimates, two
reported significantly increased risks (ranging from to adjHR
1.61, 95%CI 1.10–2.37 [42] to adjHR 1.73, 95% CI 1.28–2.34
[52]; one reported a significantly increased risk under an MSM
statistical approach (adjHR 1.48, 95% CI 1.02–2.15) but a
non-significant increased risk under a Cox proportional
hazards model (adjHR 1.25, 95% CI: 0.89–1.78) [57,64];
two reported non-significant elevated estimates (adjHR 1.27,
95% CI 0.93–1.73 and adjHR 1.28, 95% CI 0.90–1.82)
[60,62]; and two reported non-significant decreased estimates
(adjIRR 0.46, 95% CI 0.06–3.79 and adjHR 0.75, 95% CI
0.33–1.68) (Fig. 6) [53,54].
Table A2
Comparison of studies considered “Informative but with important limitations”
Study, study
population,
and whether
analysis is
new since
last systematic
review [2]
Number seroconverted/
number analyzed,
number of
seroconverters using
HC, overall HIV
incidence
Interval between
visits, length of
follow-up, loss to
follow-up and
whether follow-up
was differential by
HC status
Referent group
Overall proportion
of condom use in
population
Handling of
condom use
HC/non-HC
differences
noted at baseline
or follow-up?
Results Summary of
strengths
Summary of
weaknesses
Baeten 2007
(Kenya) [52]
Sex workers
233/1206 seroconverted
38 seroconverters using
OCs, 79 using DMPA
8.7/100 person-years
Median 35 days
between visits.
Median total
follow-up: ~
15 months
LTFU: Unclear,
Martin 1998,
reported 18% at
7.5 months [84].
Unclear if
differential.
Used tubal
ligation, used
condoms, or
used no method
Overall condom
use unclear,
reported in Martin
1998 at enrollment
as median
100%, range
0–100% [84]
Controlled for
condom
use, including
consistency.
Neither
provided.
OCs:
Crude HR: 1.58
(1.12–2.24)
adjHR: 1.46
(1.00–2.13)
DMPA:
Crude HR: 2.05
(1.56–2.70)
adjHR: 1.73
(1.28–2.34)
Primary objective
of data collection.
Monthly follow-up.
Authors argue that
behavioral
confounding less
of an issue among
high-risk women.
Presented estimates
specific to one type
of injectable (DMPA).
Met minimum quality
criteria.
Assumes
self-reported
condom use in
last week reflects
condom use in
last month. No
attempt to
explore validity
of self-reported
sexual behavior
or contraceptive
use data
presented.
High loss to
follow-up at
12 months
(~45%, open
cohort) [86].
Potential for
residual/
unmeasured
confounding.
Myer 2007 (South
Africa) [53]
Women older
than 35
53/4200 (at 6 months)
Number of seroconverters
using each method
unclear since this review
uses only data collected
up to 6 months.
2.2/100 person-years
This review
utilizes only
information
collected
between baseline
and 6 months;
thus, 6 month
interval.
LTFU: 11% at
6 months.
Not differential
by HC
use.
No HC, could
use condoms
Overall condom
use low, 1% at
enrollment,
8% most of the
time or always
during follow-up
Controlled for
condom use,
control may
not have captured
consistency.
Both provided. All estimates
based on subset
of participants
followed
through 6 months
adjIRR OCs: 0.66
(0.09–4.78)
adjIRR NET-EN:
1.60 (0.63–4.09)
adjIRR DMPA:
0.75 (0.33–1.68)
Large sample. Low
condom use in study
may have minimized
potential for
confounding by
condom use.
Disaggregated
between DMPA and
NET-EN. Met
minimum quality
criteria.
Control for
condom use
combined
“always” users
and “most
always” users
which may not
address condom
use consistency.
No attempt to
explore the
validity of
contraceptive use
data presented.
Potential for
residual/
unmeasured
confounding.
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Kleinschmidt 2007
(South Africa) [54]
Family planning
clinic attendees
23/551
11 seroconverters
using injectables
(10 using NET-EN,
1 using DMPA)
4.7/100 person-years
2–4 months
between visits
Total follow-up:
12 months
LTFU: Unclear,
at least 12% at 3
months (75/634).
Unclear if
differential.
Using non-
hormonal
methods or no
contraception,
could use
condoms
Overall condom
use, 54.2% at
enrollment
(measured as
any use during
last 3 months)
Controlled for
condom use,
including
consistency.
Unadjusted
analysis
stratified
by condom use
and no condom
use during study.
Baseline only. Injectables
Crude IRR .12
(0.45–2.78
NET-EN:
Crude HR: .77
(0.77–4.11
adjHR: 1.7
(0.64–4.84
DMPA:
Crude HR: .26
(0.03–1.97
adjHR: 0.4
(0.06–3.79
All injectab s,
restricted t
“never“ co om
users:
Crude IRR .8
(0.1–4.7)
Primary objective of
data collection.
Disaggregated
between DMPA and
NET-EN. Frequent
follow-up. Attempted
to explore validity of
self-reported sexual
behavior data. Met
minimum quality
criteria.
Lack of clarity
on loss to
follow-up.
Limited
statistical
power,
particularly for
DMPA. No
attempt to
explore the
validity of
contraceptive
use data
presented.
Potential for
residual/
unmeasured
confounding.
Morrison 2010
(reanalysis of
Morrison 2007)
(Uganda,
Zimbabwe) [57,64]
Family planning
clinic attendees
with subset of
higher-risk women
213/4435
71 seroconverters
using OCs, 87 using
DMPA
2.8/100 person-years
3 months between
visits.
Mean total
follow-up:
21.9 months
LTFU: 8% at 24
months.
Not differential
by HC use.
At baseline,
84% used
condoms, 13%
used withdrawal,
10% used
rhythm, 3%
were sterilized,
5% used a
non-HC method
During follow-up,
consistent condom
use was 51% in
non-HC,
13% in HC
2010 analysis:
Controlled for condom
use, but not consistency,
authors noted via email
that this did not affect
results
2007 analysis controlled
for condom use,
addressed consistency
(always condom use or
no sex vs. none/some
condom use)
2007 adjusted analysis
stratified by condom
use and no condom use
during study
Both provided. 2010 MSM
reanalysis:
OCs:
Crude HR: /a
adjHR: 1.1
(0.80–1.76
DMPA:
Crude HR: /a
adjHR: 1.4
(1.02–2.15
2007 Cox
analysis
OCs:
Crude HR: .02
(0.72–1.43
adjHR: 0.9
(0.69–1.42
DMPA
Crude HR: .24
(0.90–1.71
adjHR: 1.2
(0.89–1.78
2007 strati d
analysis re icted
to no cond use:
adjHR OC 1.47
(0.78–2.80
adjHR DM :
1.61 (0.85– .06)
Primary objective of
data collection. Large
sample. Frequent
follow-up and low loss
to follow-up.
Contraceptive
self-report validated in
clinic records. 2010
MSM analysis may
have addressed
time-dependent
confounding. 2007
paper provided
stratified analysis on
never condom use.
Presented estimates
specific to one type of
injectable (DMPA).
Attempted to explore
validity of
self-reported
sexual behavior and
contraceptive use data.
Met minimum quality
criteria.
Self-reported
condom use
associated with
increased HIV,
and consistent
condom use
did not
decrease HIV,
raising concern
about response
validity and
success of
statistical
adjustment.
Assumes
self-reported
condom use in
“typical month
in last 3 months”
reflects
condom use in
last 3 months.
Effect
modification by
study site
(detailed in
2007 analysis)
lacks a clear
biological
(continued on next page) 373
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Table A2 (continued)
Study, study
population,
and whether
analysis is
new since
last systematic
review [2]
Number seroconverted/
number analyzed,
number of
seroconverters using
HC, overall HIV
incidence
Interval between
visits, length of
follow-up, loss to
follow-up and
whether follow-up
was differential by
HC status
Referent group
Overall proportion
of condom use in
population
Handling of
condom use
HC/non-HC
differences
noted at baseline
or follow-up?
Results Summary of
strengths
Summary of
weaknesses
mechanism.
Potential for
residual/
unmeasured
confounding.
Reid 2010
(South Africa,
Zambia, Zimbabwe)
[41]
HSV-2 positive
women in family
planning or other
clinics
72/1358
Unclear how many
seroconverters using
HC
4.0/100 person-years
3 months between
visits.
Total follow-up:
up to 18 months.
LTFU: Unclear,
unclear if
differential.
Women using no
contraceptive
method (excluded
women using
condom as a
contraceptive
method)
At enrollment,
42% reported
ever using
condoms in last
3 months
Women reporting
condoms as
primary contraceptive
method not in
referent group.
Addressed
consistency by
controlling for any
unprotected sex.
Neither
provided.
OCs:
Crude HR: 0.93
(0.48–1.82)
adjHR: 0.91
(0.45–1.83)
Injectable
(DMPA and
NET-EN):
Crude HR:
1.01 (0.51–1.98)
adjHR: 0.94
(0.46–1.92)
Frequent follow-up.
Excluding women
using condoms for
contraception from
referent group may
equalize quality of
condom use between
groups. Attempted to
explore validity of
self-reported sexual
behavior and
contraceptive use data.
Women with missing
data more likely to
become pregnant (and
acquire HIV);
therefore unlikely to
have been using HC
— suggesting that
their exclusion would
likely lead to an effect
exaggeration, if
anything. Met
minimum quality
criteria.
Self-reported
contraceptive
info during
follow-up
captured in site
chart notes and
abstracted into
database at end
of study, which
may have
affected quality
of exposure
information.
Did not
disaggregate
between
DMPA and
NET-EN.
Lack of clarity
on loss to
follow-up.
Potential for
residual/
unmeasured
confounding.
Heffron 2012
(Seven countries
in East and
Southern
Africa) [59]
Women in a
serodiscordant
couple
73/1314
13 seroconverters using
HC, 10 using injectables
and 3 using OCs
4.09/100 person-years
3 months between
visits for HIV-
partner.
Median follow-up:
18 months
LTFU: Reported as
7% at 12 months,
13% at 24 months,
unclear if differential.
Had hysterectomy,
tubal ligation, used
condoms, or used
no contraception
During follow-up,
self-reported
condom use
was high (only
7.6% of intervals
included any
self-reported
unprotected sex)
Controlled for
unprotected
sex (thereby
incorporating
information on
self-reported
condom use
consistency).
Follow-up only. Any HC
Cox crude HR:
1.73 (0.95–3.15)
Cox adjHR: 1.98
(1.06–3.68)
MSM adjOR: 1.84
(0.98–3.47)
OCs
Cox crude HR:
1.53(0.48–4.90)
Cox adjHR: 1.80
(0.55–5.82)
Analysis of
serodiscordant couples
increases likelihood
that all participants
were equally exposed
to sexual activity with
an HIV-positive partner.
Frequent follow-up.
Low loss to
follow-up. MSM
analysis may have
addressed
Assumes self-
reported
condom use in
last month
reflects
condom use in
last 3 months.
Possible
condom over-
reporting; only
8% of intervals
involved any
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MSM adjOR: 1.63
(0.47–5.66)
Injectable (DMPA
and NET-EN)
Cox crude HR:
1.80 (0.92–3.52)
Cox adjHR: 2.05
(1.04–4.04)
MSM adjOR: 2.19
(1.01–4.74)
time-dependent
confounding. Met
minimum quality
criteria.
self-reported
unprotected
sex; yet HIV
incidence was
4.09/100
person-years.
No attempt to
explore validity
of self-reported
sexual behavior
or contraceptive
use data
presented. Did
not disaggregate
between DMPA
and NET-EN.
Potential for
residual/
unmeasured
confounding.
Heffron 2012
[Authors' reply]
(Subanalysis of
study shown
above)
[61]
HIV-negative
women in a
serodiscordant
couple
New since last
systematic review
Same as above, except
sub-analysis excluding
women in South Africa
(e.g., DMPA subanalysis)
includes 4 seroconverters
using DMPA [65]
Same as above Same as above Same as above Same as above Injectables; analysis
adding total number
of unprotected sex
acts to statistical
model
adjHR (Cox): 2.04
(1.03–4.04)
Injectables; analysis
replacing woman's
report of unprotected
sex with male
partner's report
adjHR (Cox): 2.03
(0.95–4.32)
DMPA; analysis
excluding women
from South Africa
(who may use
NET-EN) (unpublished
estimate) [65]
adjHR (Cox): 2.04
(0.81–5.15)
DMPA; analysis
excluding women
from South Africa
and also excluding
women who switched
contraceptive status at
any time in the study
Same as above, and in
addition: Sub-analyses
offer some additional
evidence that
incomplete statistical
control for sexual
behavior may not
explain findings.
Attempt to isolate
estimate for DMPA.
Met minimum quality
criteria.
Same as above.
(continued on next page)
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Table A2 (continued)
Study, study
population,
and whether
analysis is
new since
last systematic
review [2]
Number seroconverted/
number analyzed,
number of
seroconverters using
HC, overall HIV
incidence
Interval between
visits, length of
follow-up, loss to
follow-up and
whether follow-up
was differential by
HC status
Referent group
Overall proportion
of condom use in
population
Handling of
condom use
HC/non-HC
differences
noted at baseline
or follow-up?
Results Summary of
strengths
Summary of
weaknesses
adjHR (Cox): 3.93
(1.38–11.22)
Morrison 2012
(South Africa) [60]
Sexually active
women aged
16–49, recruited
from community
venues
270/5567
21 seroconverters using
OCs, 103 using DMPA,
55 using NET-EN
3.7/100 person-years
Months 1, 3, and
every 3 months
thereafter
Follow-up from
9–24 months
LTFU not reported
in manuscript (but
89.9% at 1 yr in
Kaplan-Meier
analysis), (C.
Morrision, personal
communication,
2012) unclear if
differential.
No use of HC;
excluded IUD
users and women
with hysterectomy;
included women
using male or
female condoms,
male or female
sterilization,
diaphragm,
traditional methods,
or not using any
contraceptive
method
About 23%
reported any
condom use at
enrollment;
varied significantly
by contraceptive
method
Controlled for
condom use, did
not address
consistency.
Baseline only OCs
Cox adjHR: 0.88
(0.49–1.30)
MSM adjHR: 0.84
(0.51–1.39)
DMPA
Cox adjHR: 1.27
(0.93–1.73)
MSM adjHR: 1.28
(0.92–1.78)
NET-EN
Cox adjHR: 0.87
(0.60–1.25)
MSM adjHR: 0.92
(0.64–1.32)
Large sample.
Frequent follow-up.
Disaggregated
between DMPA and
NET-EN. Low loss to
follow-up. MSM
analysis may have
addressed time-
dependent
confounding.
Attempted to validate
of self-reported
contraceptive use. Met
minimum quality
criteria.
Analysis did not
address
consistency of
condom use. No
attempt to
explore validity
of self-reported
sexual behavior
presented.
Potential for
residual/
unmeasured
confounding.
Wand 2012 (Durban,
South
Africa) [42]
Women enrolled
in a phase III trial
testing effectiveness
of vaginal
gel for HIV
prevention
Included in last
review, newly
considered in this
review to meet
criteria for
“Informative but
with important
limitations”
162/2236 seroconverted
8 seroconverters using
OCs, 90 seroconverters
using injectables (61
using DMPA and 29
using NET-EN [85])
Overall HIV incidence
not reported
Quarterly visits.
Total follow-up:
not reported
LTFU: Not
reported in
manuscript (noted
as approximately
10%) [87], unclear
if differential
Male or female
condoms, tubal
ligation, vasectomy,
intrauterine device,
traditional methods,
no contraceptive
method
At enrollment,
60% of participants
reported
using condoms
at last sex, varied
significantly by
contraceptive
method.
Controlled for
condom use at last
sex
Baseline only. OCs
adjHR: 0.95
(0.62–1.46)
Injectables
adjHR: 2.02
(1.37–3.00)
DMPA adjHR: 1.61
(1.10–2.37) [85]
NET-EN adjHR: 2.54
(1.61–3.97) [85]
Frequent follow-up.
Met minimum quality
criteria.
Information on
loss to follow-
up not provided.
No attempt to
explore validity
of self-reported
sexual behavior
or contraceptive
use data
presented.
Disaggregation
of injectable
types not
reported in
publication
(though provided
on request) [85].
Authors stated
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in personal
communication
that they “do
not think that
we can infer
any biological
conclusion
between HC
and HIV based
on our data.”
[87] Injectable
group contained
a very small
number (n=3)
of Norplant
users. Potential
for residual/
unmeasured
confounding.
McCoy 2013 [62]
South Africa
and Zimbabwe
Sexually active
women
participating
in a phase III
effectiveness
trial of the
diaphragm and
lubricant gel for
HIV prevention
New since last
systematic
review
283/4913 women
seroconverted (271/4913
seroconversions included
in published estimates)
102 seroconverters using
injectables (63 using
DMPA, 17 using
NET-EN, 22
injectable type unclear)
and 61 seroconverters
using OCs (44 using
COCs, 17 using POPs)
4.06/100 person-years
3 months between
visits.
Median duration of
follow-up: 18 months
LTFU: unclear. In
parent study [88],
7% did not
complete scheduled
closing visit.
Unclear if
differential.
Used condoms,
traditional
methods,
withdrawal,
nonhormonal
IUDs, diaphragm,
spermicides,
sterilization, or
no contraception
At enrollment,
69% reported
condom use at
last sex, which
differed
significantly by
contraceptive
method. At
enrollment,
condom use as
reported in the last
3 months
was 29% “Never”,
39% “Sometimes”,
and 31% “Always”;
this also differed
significantly by
contraceptive
method.
Controlled for
condom
use (frequency in the
past 3 months) in
Cox model adjusted
for baseline
and time-varying
covariates; and in
IPTW MSM model.
Baseline only. adjHR Cox
site-adjuste only
OC overall 0.82
(0.58–1.15
COC: 0.78 0.53–1.12)
POP: 0.91 .49–1.50)
Injectables verall:
1.32 (1.00– .74)
DMPA: 1.
(0.84–1.62
NET-EN: 1 0
(0.72–2.35
adjHR Cox model
adjusted fo baseline
covariates
OC overall 0.84
(0.57–1.22
COC: 0.80 0.53–1.19)
POP: 0.94 .50–1.59)
Injectables verall:
1.27 (0.94– .72)
DMPA: 1.
(0.84–1.74
NET-EN: 1 5
(0.58–1.95
adjHR Cox model
with robus tandard
errors to a ount for
within-sub t
Large sample.
Disaggregation of
COCs and POPs
reported in
publication. Frequent
follow up. MSM
analysis may have
addressed
time-dependent
confounding.
Lack of clarity
on loss to
follow up. No
attempt to
explore validity
of self-reported
sexual behavior
or contraceptive
use data
presented.
Disaggregation
of injectable
types not
reported in
publication
(though
provided on
request) [82].
Potential for
residual/
unmeasured
confounding.
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Table A2 (continued)
Study, study
population,
and whether
analysis is
new since
last systematic
review [2]
Number seroconverted/
number analyzed,
number of
seroconverters using
HC, overall HIV
incidence
Interval between
visits, length of
follow-up, loss to
follow-up and
whether follow-up
was differential by
HC status
Referent group
Overall proportion
of condom use in
population
Handling of
condom use
HC/non-HC
differences
noted at baseline
or follow-up?
Results Summary of
strengths
Summary of
weaknesses
correlation and
separate baseline
hazards for each of
the three study sites,
adjusted for baseline
and time-varying
covariates
COC: 0.86 (0.58–1.28)
POP: 0.98 (0.56–1.73)
Injectables overall: 1.37
(1.01–1.85)
DMPA: 1.28
(0.90–1.82) [82]
NET-EN: 1.33
(0.76–2.33) [82]
adjHR IPTW MSM
injectables overall:
1.34 (0.75–2.37)
OC overall: 0.86
(0.32–1.78)
Note: only disaggregated
injectable Cox estimates
provided in personal
communication,
disaggregated MSM
injectable estimates
not possible due to
violation of the
positivity assumption.
adj, adjusted; HR, hazard ratio; IRR, incidence rate ratio; LTFU, loss to follow-up; OR, odds ratio.
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Original references retrieved (published between December 15, 2011 and January 15, 2014)
n = 400 
Reports excluded based on title/abstract review
n = 397
Reports assessed for eligibility
n = 3
Reports excluded
n = 0
New reports included
(n = 3)
2 new studies
1 sub-analysis of a  
previously included
study
Fig. 1. Study selection. Note: We relied upon the search from a previous systematic review [2] to identify all relevant studies published prior to December 15, 2011.
Fig. 2. Use of oral contraceptives and HIV acquisition (all 18* studies, regardless of quality). Error bars show 95% CIs. Studies are arranged in order of
decreasing magnitude of risk estimate, except if a single study disaggregated POPs and combined oral contraceptives [COCs], in which case both estimates are
adjacent (as indicated by a box around the study identifiers). For studies which reported both Cox and MSM estimates, both estimates are displayed on a single
line (also identified by bracket signs). OR, odds ratio, IRR, incidence risk ratio. HR, hazard ratio. * Data from Saracco and colleagues' study are not shown
because risk could not be calculated since no seroconversions occurred in the hormonal contraception group. †Analysis showed statistically significant findings
at p=.05 (marker also displayed in red). ¥ Different statistical models adjusted for slightly different confounders.
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Fig. 3. Use of injectable contraceptives and HIV acquisition (all 18 studies, regardless of quality). Error bars show 95% CIs. Studies are arranged in order of
decreasing magnitude of risk estimate, except if a single study provided disaggregated estimates for DMPA and NET-EN, in which case both estimates are
adjacent (as indicated by a box around the study identifiers). For studies in which both Cox proportional hazards (Cox) and marginal structural model (MSM)
analyses were reported, both are displayed on a single line (also identified by bracket signs containing two estimates), except for one study in which both Cox and
MSM estimates for both DMPA and NET-EN separately were unavailable [62,82]. OR, odds ratio, IRR, incidence risk ratio. HR, hazard ratio. *Analysis showed
significant findings at p=.05 (marker also displayed in red). †Estimate for Cox model taken from slightly updated analysis which controlled for total number of
unprotected sex acts. § Unpublished estimates disaggregated by injectable type. ¥ Different statistical models adjusted for slightly different confounders.
380 C.B. Polis et al. / Contraception 90 (2014) 360–390Of five studies reporting NET-EN estimates, one reported a
significantly increased risk (adjHR 2.54, 95% CI 1.61–3.97)
[42]; three reported non-significant elevated estimates
(ranging from adjHR 1.33, 95% CI 0.76–2.33 to adjHR
1.76, 95% CI 0.64–4.84) [53,54,62]; and one reported non-
significant decreased estimates (adjHR 0.87, 95% CI 0.60–
1.25 or adjHR 0.92, 95% CI 0.64–1.32, depending upon the
statistical model used) (Fig. 7) [60].
Of five studies that provided separate estimates for both
DMPA and NET-EN (Fig. 5), four reported estimates within
the same study for NET-EN that were slightly or sub-
stantially higher than the DMPA estimates [42,53,54,62],
while one study reported an estimate for NET-EN that was
lower than for DMPA [60].3.2.3. Implants
Data on implants were limited. Only one study was
classified as “informative but with important limitations”,
and it reported a non-significantly increased risk of HIV
acquisition with implants, with a wide 95% confidence
interval (adjHR 1.6, 95% CI 0.5–5.7) [66].3.2.4. Effect modification
One study by Morrison et al. reported that both DMPA
and OCs were associated with increased HIV acquisition in
women aged 18–24, but not in women aged 25 and older
[57]. However, most studies have not detected evidence for
effect modification by age [52–54,59], including the second-
largest analysis to date (p=.60) [62].
Similarly, the Morrison et al. study reported that DMPA
was associated with increased HIV risk (adjHR 4.5, 95% CI
2.0–10.2) in HSV2-negative, but not HSV2-positive women
(adjHR 1.0, 95% CI 0.7–1.6) [57]. Other studies have not
found evidence for effect modification by HSV2 status
[52,59], including a study of 2057 HSV2-negative women
and 2856 HSV2-positive women (interaction term p=.21 for
the effect of DMPA on HIV acquisition) [62].
The Morrison et al. study also reported a significant
interaction by study site (point estimates for both OCs and
DMPAwere above 1.0 inUganda, but below1.0 in Zimbabwe)
[64] (an interaction that was not assessed in a later MSM
analysis [57]). That study reported no effect modification by
reported condom use at baseline, by participant behavioral risk,
or by prevalent chlamydia or gonorrhea [64].
Table A3
Factors considered⁎ and controlled for in multivariate analysis, among studies classified as “informative but with important limitations”
Kiddugavu
2003
[51]
Baeten
2007
[52]
Myer
2007
[53]
Kleinschmidt
2007
[54]
Morrison
2007/10
[57,64]
Reid
2010
[41]
Wand
2012
[42]
Heffron
2012
[59,61]
Morrison
2012
[60]
McCoy
2013
[62]
Condom use Considered X X X X X X X X X X
Controlled X X X X X X X X X X
Number of sex partners
(or concurrent partners)
Considered X X X X X X X X X X
Controlled X X X X X X X X X
Age Considered X X X X X X X X X X
Controlled X X X X X X X X X X
Education Considered X X X X X X X X X
Controlled X X X
Married/lives with partner Considered X X X X X X X
Controlled X X X X X X
Coital frequency Considered X X X X X X
Controlled X X† X
Age at sexual debut Considered X X
Controlled
Parity Considered X X X X X
Controlled X X
Pregnancy Considered X X X X X
Controlled X X
Breastfeeding Considered X
Controlled
Sex work Considered All SW X X X
Controlled All SW X X X
GUD Considered X X X X X
Controlled X X
HSV2 Considered X X X X
Controlled X X
HPV Considered X
Controlled X
BV Considered X X X X
Controlled X X
Chlamydia/Gonorrhea/
Trichomoniasis
Considered X X X X X X X X X
Controlled X X X X X
Vaginal discharge or discomfort, Candida Considered X X X
Controlled X X
Vaginal washing/wiping Considered X X
Controlled X
Abnormal epithelial findings Considered X
Controlled X
Alcohol use Considered X
Controlled X
Partner risk Considered X All HIV+ X X
Controlled X All HIV+ X X
Male circumcision status Considered X X
Controlled
New sex partners recently Considered X X X X
Controlled X X X X
Recent HIV+partner Considered X All HIV+
Controlled All HIV+
Partner plasma VL Considered X
Controlled X
Partner CD4 Considered X
Controlled
Housing type/status Considered X X
Controlled X
Site Considered X X X X
Controlled X X X
Own income Considered X X
Controlled
Partner own income Considered X
Controlled X
(continued on next page)
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Table A3 (continued)
Kiddugavu
2003
[51]
Baeten
2007
[52]
Myer
2007
[53]
Kleinschmidt
2007
[54]
Morrison
2007/10
[57,64]
Reid
2010
[41]
Wand
2012
[42]
Heffron
2012
[59,61]
Morrison
2012
[60]
McCoy
2013
[62]
Race Considered X
Controlled
Anal sex Considered X X
Controlled X
Religion Considered X
Controlled X
Syphilis Considered X
Controlled X
Injection drug use Considered X
Controlled X
Diaphragm use over past 3 months Considered X
Controlled X
BV, bacterial vaginosis; SW, sex worker; GUD, genital ulcer disease; HPV, human papillomavirus; HSV2, seropositive for herpes simplex virus 2; “all HIV+”
— all partners were HIV positive as data were collected in study of serodiscordant couples.
⁎ Some confounders were considered but not controlled for due to a lack of confounding in those data; and some factors listed on this table are not relevant
to all studies (i.e., site or race in homogeneous populations).
† While most confounding factors are detailed in the original analysis [59], the sensitivity analysis reported in a subsequent publication [61] added a control
for total number of unprotected sex acts.
Fig. 4. Use of oral contraceptives and HIV acquisition (eight studies considered informative but with important limitations). Error bars show 95% CIs. Studies are
arranged in order of decreasingmagnitude of risk estimate, except if a single study disaggregated POPs and combined oral contraceptives [COCs], in which case both
estimates are adjacent (as indicated by a box around the study identifiers). For studies which reported both Cox proportional hazards (Cox) and marginal structural
model (MSM) estimates, both estimates are displayed on a single line (also identified by bracket signs). OR, odds ratio, IRR, incidence risk ratio. HR, hazard ratio.
*Analysis showed significant findings at p=.05 (marker also displayed in red). ¥ Different statistical models adjusted for slightly different confounders.
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Fig. 5. Use of injectable contraceptives and HIV acquisition (nine studies considered informative but with important limitations). Error bars show 95% CIs.
Studies are arranged in order of decreasing magnitude of risk estimate, except if a single study disaggregated DMPA and NET-EN, in which case both estimates
are adjacent (as indicated by a box around the study identifiers). For studies in which both Cox proportional hazards (Cox) and marginal structural model (MSM)
analyses were reported, both are displayed on a single line (also identified by bracket signs), except for one study in which both Cox and MSM estimates for both
DMPA and NET-EN separately were unavailable [62,82]. OR, odds ratio, IRR, incidence risk ratio. HR, hazard ratio. *Analysis showed significant findings at
p=.05 (marker also displayed in red). †Estimate for Cox model taken from slightly updated analysis which controlled for total number of unprotected sex acts.
§ Unpublished estimates disaggregated by injectable type; only disaggregated Cox estimates provided in McCoy et al. 2013, disaggregated MSM estimates not
possible due to violation of the positivity assumption. ¥ Different statistical models adjusted for slightly different confounders.
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4.1. Methodological considerations in studies considered
informative but with important limitations
Discussion of multiple key methodological consider-
ations, such as potential for confounding, frequency and
accuracy of variable measurement, aim of data collection,
and statistical power and precision is available in our
previous review [2]. Below, we expand upon the
discussion on the handling of confounding by condom
use, and provide an overview of considerations related to
“total” and “direct” effects.
4.1.1. Considerations on measurement and parameterization
of condom use
Analytic approaches to addressing potential confounding
by condom use vary considerably across studies (Tables A1
and A2), and is one of several reasons why study findings
may vary. Reliable, valid, self-reported measurement of
condom use is difficult: individuals may not remember
whether, how often, and with whom they used condoms over
a given time period; they may deliberately misreport due to
embarrassment or social desirability bias [67]; or they may
unintentionally misreport (e.g., if they experience anunrecognized condom failure). Adjustment for a poorly-
measured confounding variable can in theory lead to
adjusted estimates of effect which are more biased than the
unadjusted estimates [68].
Studies approached the issue of condom use in different
ways. For example, one study restricted analysis to time
periods in which no condom use was reported for either
contraception or HIV prevention, in an attempt to minimize
the potential for differential condom use between users and
non-users of HC [63]. Some studies attempt to control
statistically for some measure of condom use, such as the
proportion of unprotected sex acts, or “never-sometimes-
always” condom use. Studies varied with respect to whether
questions about condom use were pertinent to the entire
intersurvey interval, or only a subset of time during that
interval. Some studies asked only about condom use during
the most recent sex act and assumed this to be representative
of participants' “typical” condom use. This last measure may
reduce recall bias, but cannot eliminate intentional or
unintentional misreporting; a recent review noted that in
several studies semen was detected on vaginal swabs taken
from 6–36% of women who reported no sex in the past 2
days, and in 13–39% of women who reported protected sex
only [69].
Fig. 6. Use of DMPA (or unspecified injectable) and HIV acquisition (among studies considered informative but with important limitations). Error bars show 95%
CIs. Studies are arranged in order of decreasing magnitude of risk estimate. For studies in which both Cox proportional hazards (Cox) and marginal structural
model (MSM) analyses were reported, both are displayed on a single line (also identified by bracket signs) IRR, incidence risk ratio. HR, hazard ratio. *Analysis
showed significant findings at p=.05 (marker also displayed in red). †Estimate for Cox model taken from slightly updated analysis which controlled for total
number of unprotected sex acts. §Unpublished estimates disaggregated by injectable type; only disaggregated Cox estimates provided in McCoy et al. 2013,
disaggregated MSM estimates not possible due to violation of the positivity assumption. ¥ Different statistical models adjusted for slightly different confounders.
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As discussed in previous work [35], the analytic approach
used by an epidemiologic study has implications for the
interpretation of its findings. In particular, model results
from reports reviewed here may be estimating a “direct
effect” of HC on HIV not mediated by sexual behaviors
(which can be roughly conceived of as an estimate of the
HIV acquisition risk per coital act unprotected by condoms,
comparing HC users to non-users), the “total effect” (which
would include these biological effects as well as behavioral
changes that may be affected by HC use, such as decreased
condom use or increased coital frequency), or neither (due to
vague or poor model specification). The authors of this
review determined that the “direct effect” (representing a
more biological effect) is more desirable for the purpose of
the World Health Organization Medical Eligibility Criteria
for Contraceptive Use, which is intended to provide global
guidance for policy makers. Unfortunately, estimating direct
effects may require statistical assumptions additional to those
necessary to estimate total effects.
While some argue that a “total effect” is useful to
understand the full impact of a given HC method on HIV
acquisition, behavioral changes stemming from use of HC
may be specific to geography, culture, socioeconomic status,
and other factors. Studies estimating a total effect may be
less generalizable (if behaviors are affected differently indifferent populations), and may also be less informative for
women for whom use of HC might modify their behavior in
ways not represented by population averages. For example, a
woman whose partner has always refused to use condoms
will not reduce condom use as a result of HC initiation, even
if most women who initiate HC reduce condom use. DMPA
may be an important option for such a client if no direct
effect of DMPA on HIV acquisition is expected, even if a
total effect (mediated by reduced condom use) is expected.
Thus, direct effects (which are not mediated by behaviors of
individuals) may be of more use for individual decision-
making, and are thus preferred in this discussion.
No published study has explicitly stated whether the
analysis attempts to estimate total or direct effects. We
assumed that MSMs are generally estimating total effects
[70] and time-updated Cox models, which adjust for time-
varying mediators such as condom use, are estimating
something closer to direct effects. Nonetheless, we included
MSM estimates in this review in the hopes of contextualizing
direct effects. Although the models should theoretically
produce different results, in practice most MSM estimates
were very similar to adjusted Cox effects from the same
studies. This suggests that mediation by measured sexual
behavior was not substantial in this setting: however, since
sexual behavior may have been mismeasured, it would be
rash to conclude that there is no mediation per se.
Fig. 7. Use of NET-EN and HIV acquisition (among studies considered informative but with important limitations). Error bars show 95% CIs. Studies are
arranged in order of decreasing magnitude of risk estimate. For studies in which both Cox proportional hazards (Cox) and marginal structural model (MSM)
analyses were reported, both are displayed on a single line (also identified by bracket signs). IRR, incidence risk ratio. HR, hazard ratio. *Analysis showed
significant findings at p=.05 (marker also displayed in red). § Unpublished estimates disaggregated by injectable type; only disaggregated Cox estimates
provided, disaggregated MSM estimates not possible due to violation of the positivity assumption.
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As noted elsewhere, it is imperative to continually refine
quality assessment criteria as this complex body of literature
continues to grow [35]. For example, older systematic reviews
of this issue may have included cross-sectional studies; doing
so currently would add little to what is known. As such, we
modified the study quality assessment framework used in the
previous systematic review [2]. Specific modifications
included: (1) relaxing our stipulations about adequate control
for condom use (rationale provided below); (2) considering
studies lower quality if one out of two (instead of two out of
three) major flaws existed; (3) no longer specifying the level of
loss to follow up that would be considered a major flaw (as the
cutoff chosen could be viewed as arbitrary), and (4) providing
additional specificity to our definition of “unclear measure-
ment of exposure to HC,” by newly including a requirement
that the intersurvey interval be less than or equal to 6 months
(or, if over 6 months, that detailed information on use of
contraceptives in the interim period be collected and analyzed).
While a Cochrane review estimated that consistent condom
use decreased heterosexual HIV transmission by 80% as
compared with no condom use [71], a study examining four
different measures of condom use (condom use since last visit,
condom use at last sex, frequency of condom use, and count ofunprotected acts) found that no measure of condom use was
significantly associated with reduced risk of sexually trans-
mitted infections or HIV. All four measures were significantly
correlated with reduced pregnancy risk; the strongest
protective association was observed with the frequency of
use condom variable [72]. Since no measurement of condom
use has been validated as superior, we did not distinguish
between methods of handling condom use, so long as some
attempt was made to address this issue.4.3. Limitations
All currently available epidemiological data on this issue
come from observational studies and are vulnerable to residual
confounding, which can mask a real effect or generate a
spurious effect. Most currently available information relates to
OCs and injectables (including DMPA and NET-EN).
Separation of data according to specific hormonal content or
formulation is not consistently performed across studies.
Future analyses should provide disaggregated estimates, given
that different hormonal formulations may have different
biological effects on risk of HIV acquisition [35]. Data are
extremely limited for implants, and no data are available for
contraceptive patches, rings, or hormonal IUDs.
Fig. 8. Funnel plots (A: OCs and HIV acquisition, B: Injectables and
HIV acquisition).
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of literature, including of measurement of exposure and of
potential confounders. For example, measurement of
exposure to OC use (which requires daily action by the
user) is more challenging than measurement of exposure to
injectable contraceptive use (which requires user action
only every 3 months). In some HIV prevention trials,
women reporting OC use demonstrate comparable preg-
nancy incidence to women using no contraceptive method;
raising the possibility of limited or inconsistent actual
exposure to OC use [73]. Thus, the possibility exists that the
null effect of OCs reported in most studies reflects a lack of
actual exposure, rather than a true lack of association
between OCs and risk of HIV acquisition. On the other
hand, while pregnancy risk by contraceptive type is not
consistently reported, some studies in this review demon-
strate a reduction in pregnancy risk among OC users [41].
Given this issue, it is recommended that future observational
analyses compare pregnancy rates [35].
Several innovative analytic approaches have been used in
recent studies. For example, two studies used data fromserodiscordant couples which may help control for differ-
ences in exposure to an HIV-infected partner, and both
highlight the importance of using various analytic techniques
(such as restriction to non-condom users, or assessing male
partner report of condom use) to assess whether primary
findings remain robust (thereby testing concerns about the
validity of data on self-reported sexual behaviors) [61,63].
However, several methodological challenges remain, and are
reviewed elsewhere, along with recommended approaches to
improve the quality of evidence in future studies [35].
We are aware of anecdotal evidence that a non-significant
preliminary finding for the effect of DMPA use on HIV
acquisition was not pursued for publication in at least one case,
due to the lack of a statistically significant finding. This is
problematic; if studies with significant results are more likely to
be published, a systematic literature review is unable to capture
the universe of relevant information on this issue [74]. However,
funnel plots (Fig. 8) displayed only moderate asymmetry.
In addition to the limitations of individual studies, there are
limitations to this systematic review. There is no agreed upon,
comprehensive, objective method to assessing the quality of
studies in this complex body of literature; conclusions may vary
depending upon what quality criteria are applied. As noted
above, discussions on ideal approaches to evaluating this
literature should continue to evolve.
4.4. Unpublished evidence
For methodological reasons, we did not include unpublished
analyses in this systematic review. Researchers have noted that
differences between data presented in conference abstracts and
published papers are “frequent and occasionally major,” [75]
and that “the inclusion of data from unpublished studies [in
systematic reviews] can itself introduce bias” given that
“unpublished trials may be of lower methodological quality
than published trials.” [76] Furthermore, there is no systematic
manner in which to search grey literature, and moreover,
thorough assessment of study quality is often challenging or
impossible based on information provided in a conference
presentation. We are aware of one analysis published
subsequent to our cutoff date (January 15, 2014) [77], and of
four relevant presentations on this issue [78–81]. Any analyses
newly reported in academic journals since the cutoff for
inclusion in this review will be carefully examined and reported
at the next technical consultation on this issue.
4.5. Conclusions
We considered nine of 22 studies to be “informative but
with important limitations”.
4.5.1. Oral contraceptives
The preponderance of data suggests that OCs do not
increase risk of HIV acquisition. Only one study (of eight
considered “informative but with important limitations”
which assessed OCs) reported a modestly elevated statisti-
cally significant risk estimate (adjHR 1.46, 95% CI
387C.B. Polis et al. / Contraception 90 (2014) 360–3901.00–2.13); all other studies found no significant effect,
including a study which provided separate information about
COCs and POPs [62].4.5.2. Injectables
4.5.2.1. All injectables (i.e., either DMPA alone, or DMPA
and NET-EN combined). The observational data on
injectable contraceptive use and risk of HIV acquisition
remain difficult to interpret. Modifications to our quality
framework for selecting studies changed slightly the group
of studies considered to be higher quality (i.e., classified as
“meeting minimum quality criteria” in the previous review,
or “informative but with important limitations” in the current
review). Specifically, we removed one study with non-
significant effects for DMPA from the higher quality group
[51] and added one study with significant effects for both
DMPA and NET-EN [42]. In addition, new sub-analyses by
Heffron et al. [61] lend some additional confidence that
incomplete statistical control for sexual behaviors (e.g., self-
reported condom use, coital frequency) may not explain the
statistically significant findings observed for injectables in
their original analysis. Another separate new subanalysis by
Heffron et al. suggested that the estimate for all injectables (as
presented in the original paper) is similar in magnitude to the
best possible approximation of an estimate for DMPA
(as presented in the subanalysis). However, those sub-analyses
contained few incident HIV infections, and some researchers
have questionedwhether condom use was over-reported based
on the high pregnancy rates observed in this study [26,29].
On the other hand, one large, newly included study did
not find statistically significant effects on HIV risk for either
DMPA or NET-EN. Combining DMPA, NET-EN, and uns-
pecified injectables into a single exposure category resulted
in a significant finding (adjHR: 1.37, 95% CI 1.01–1.85)
under a Cox proportional hazards model, and a similar but
non-significant point estimate under a MSM approach
(adjHR: 1.34, 95% CI 0.75–2.37) [62]. In addition, the
modification to the quality framework relating to intersurvey
interval resulted in the use of HC method estimates for the
study by Myer et al. only from the first 6 month survey
interval, as subsequent intervals were longer than 6 months
[53]. The new DMPA point estimate remained non-
significant, and was slightly smaller than the previous one
(adjHR 0.96, 95% CI 0.58–1.59 in the previous review vs.
adjHR 0.75, 95% CI 0.33–1.68 in the current), while the
NET-EN estimate remained non-significant but with the
direction of effect changed (from adjHR 0.79, 95% CI
0.31–2.20 previously vs. adjHR 1.60, 95% CI 0.63–4.09
currently). Finally, results from one study [57,64] demon-
strate a statistically significant effect of DMPA on HIV risk
using a MSM approach but not a Cox model approach. Cox
models are a closer approximation to the direct effect, our
effect of interest. Thus, new data published between
December 15, 2011 and January 15, 2014 for injectables,particularly DMPA, do not resolve the critical question of
whether progestin-only injectables increase HIV risk.
4.5.2.2. NET-EN. One previously identified study which
was newly classified as “informative but with important
limitations” reported a statistically significant increased risk
of HIV acquisition with NET-EN [42]. One new study
reported no increased HIV risk with NET-EN use [62], and
the direction of another estimate (for the study in which we
restricted to only data from the 6-month follow-up visit)
reversed but remained non-significant (estimate changed
from adjIRR 0.79, 95% CI 0.31–2.20 previously, to adjIRR
1.60, 95% CI 0.63–4.09 currently) [53]. These new data add
heterogeneity to evidence on NET-EN.
4.5.3. Implants
Data on contraceptive implants and HIV acquisition are
extremely limited. No studies have suggested a statistically
significant increased risk of HIV acquisition among implant
users, though the limited number of studies examining this
method and the wide confidence intervals for existing
estimates preclude clear interpretation of the effects of
implants on HIV acquisition. Ideally, future studies assessing
implants will separately assess etonogestrel and levonorges-
trel implants, which may have different biological effects.
4.5.4. Summary
In conclusion, and consistent with our previous review,
evidence available at present suggests that OCs do not
increase risk of HIV acquisition. One new study suggests
that this finding may extend to both COCs and POPs, and
adds to very limited data assessing non-injectable progestin-
only HC methods. Uncertainty persists regarding the
association between DMPA and HIV risk. Newly published
analyses are in the direction of an elevated risk; taken
together with prior evidence, the new data lead to a moderate
increase in the consistency of estimates of the effect of
DMPA on HIV risk. Still, several of the largest studies
reported no statistically significant increased HIV risk
among DMPA users, contributing to continued uncertainty.
None of three studies in our previous review suggested a
significantly increased risk for NET-EN, whereas one of five
available estimates in our current review does. Four of the
five studies that presented both DMPA and NET-EN
estimates reported measures of effect for NET-EN that
were slightly or substantially higher than for DMPA, though
the 95% confidence intervals overlapped substantially in all
cases. Data are limited for implants; neither of two estimates
showed a statistically significant increased risk, but only one
was considered “informative but with important limitations”
and this estimate had limited statistical power.
Women choosing progestin-only injectable contracep-
tives should be informed of the current uncertainty regarding
whether use of these methods is associated with an increased
risk of HIV acquisition, and similar to all women at risk of
HIV, should be empowered to access and use condoms and
388 C.B. Polis et al. / Contraception 90 (2014) 360–390other HIV preventative measures. Access to a range of
contraceptive options and to HIV preventive measures is
critical. Data for OCs do not suggest an increased risk of HIV
acquisition, but programs, practitioners, and women urgently
need guidance on how to optimize health decisions in the face
of inconclusive data for progestin-only injectable contracep-
tion and of limited data for other HC methods.
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Appendix A. Search strategy
Our search strategy included papers published in any
language, and used the following date limits: Dec 15, 2011
(the date on which the search strategy for our previous
systematic review ended) through Jan 15, 2014.
The following search strategy was performed in PubMed:
(((hormonal AND contracepti*) OR (“hormonal methods”))
OR ((progestin* OR progestins[MeSH] OR Progesterone
[MeSH] OR progestogen* OR progestagen*) AND contra-
cept*) OR (oral contracept*) OR ((((depo OR depot) AND
medroxyprogesterone) OR depomedroxyprogesterone OR
depo OR depot OR dmpa OR “net en” OR NET-EN OR
“norethisterone enanthate” OR norethisterone-enanthate
OR Medroxyprogesterone 17-Acetate[MeSH]) AND (con-
tracept* OR inject*)) OR (((levonorgestrel OR etonogestrel)
AND implant) OR (uniplant OR jadelle OR implanon OR
norplant OR norplant2 OR sino-implant)) OR (contraceptives,
postcoital[MeSH] OR (contracept* AND (emergency OR
postcoital OR “post coital”)) OR “ulipristal acetate” OR “Plan
B” OR mifepristone) OR ((levonorgestrel AND (intrauterine
devices[MeSH] OR iud OR iucd OR ius OR “intrauterine
system” OR “intra-uterine system” OR “intrauterine device”
OR “intra-uterine device”)) OR mirena) OR ((combin* AND
inject* AND contracept*) OR ((“once a month” OR monthly)
AND inject* AND contracept*) OR (cyclofem OR lunelle OR
mesigyna OR “cyclo provera” OR cycloprovera)) OR ((((con-
traceptive devices[MeSH] OR contraceptive agents[MeSH])
AND ring) OR nuvaring OR “nuva ring”)) OR ((((contraceptive
devices[MeSH]OR contraceptive agents[MeSH])ANDpatch)OR “ortho evra” OR orthoevra)) AND ("HIV Seropositivi-
ty"[MeSH] OR "HIV"[MeSH] OR "HIV Infections"[MeSH]
OR "Acquired Immunodeficiency Syndrome"[MeSH] OR
“HIV progression” OR “HIV disease progression” OR “HIV
shedding” OR “viral shedding” OR “HIV transmission” OR
“Virus Shedding”[MeSH]) AND Humans[MeSH]) OR
(injectable contracepti* HIV) OR (oral contracepti* HIV).
The following search strategy was performed in Embase:
hormonal AND contracepti* OR ‘hormonal methods’ OR
(progestin* OR ‘progestins’/exp OR ‘progesterone’/exp OR
progestogen*OR progestagen*AND contracept*) OR (‘oral’/
exp AND contracept*) OR (depo OR depot AND ‘medrox-
yprogesterone’/exp OR depomedroxyprogesterone OR depo
OR depot OR dmpa OR ‘net en’OR ‘norethisterone enanthate’/
exp OR ‘medroxyprogesterone’/exp AND ‘17 acetate’ AND
(contracept* OR inject*)) OR (‘levonorgestrel’/exp OR ‘etono-
gestrel’/exp AND ‘implant’/exp) OR ‘uniplant’/exp OR
‘jadelle’/exp OR ‘implanon’/exp OR ‘norplant’/exp OR nor-
plant2 OR ‘sino implant’ OR (contraceptives, AND postcoital)
OR (contracept* AND (‘emergency’/exp OR postcoital OR
‘post coital’)) OR ‘ulipristal acetate’/exp OR ‘plan b’/exp OR
‘mifepristone’/exp OR (‘levonorgestrel’/exp AND (‘intrauter-
ine’/expAND ‘devices’/expOR ‘iud’/expOR ‘iucd’/expOR ius
OR ‘intrauterine system’ OR ‘intra-uterine system’ OR
‘intrauterine device’/exp OR ‘intra-uterine device’/exp)) OR
‘mirena’/expOR (combin*AND inject* AND contracept*) OR
(‘once a month’ OR monthly AND inject* AND contracept*)
OR ‘cyclofem’/exp OR ‘lunelle’/exp OR ‘mesigyna’/exp
OR ‘cyclo provera’/exp OR ‘cycloprovera’/exp OR
(‘contraceptive’/exp AND ‘devices’/exp OR ‘contraceptive’/
exp AND agents AND ring) OR ‘nuvaring’/exp OR ‘nuva ring’
OR (‘contraceptive’/exp AND ‘devices’ /exp OR
‘contraceptive’/exp AND agents AND patch) OR ‘ortho
evra’/exp OR orthoevra AND (‘hiv seropositivity’/exp OR
‘hiv’/exp OR ‘hiv infections’/exp OR ‘acquired immunodefi-
ciency syndrome’/exp OR ‘hiv progression’ OR ‘hiv disease
progression’ OR ‘hiv shedding’ OR ‘viral shedding’/exp OR
‘hiv transmission’ OR ‘virus shedding’/exp) AND ‘humans’/
exp OR (injectable AND contracepti* AND ‘hiv’/exp) OR
(‘oral’/exp AND contracepti* AND ‘hiv’/exp) AND
[humans]/lim AND [15-12-2011]/sd NOT [15-1-2014]/sd.References
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